Neurological disorder

Local Non-profit Announces The Ultimate Charity Climb, "ATL on STAIRoids"

Retrieved on: 
Tuesday, March 21, 2023
Lazarus, Exercise, Music, Food, Drink, Health, Friends, ANI, Atlanta United FC, Atlanta Falcons, ATL, DSM-IV codes, Movement disorder, Multiple sclerosis, MS, Alzheimer's disease, Parkinson's disease, Corporation, Mercedes-Benz Stadium, Diagnosis, Neurological disorder, ANF, Pharmaceutical industry, Epilepsy

The exciting, interactive charity fundraising event is open to everyone eight years and older.

Key Points: 
  • The exciting, interactive charity fundraising event is open to everyone eight years and older.
  • This climb event is dedicated to everyone touched by chronic neurological diseases like Multiple Sclerosis (MS), Parkinson's, Epilepsy, and Alzheimer's.
  • Dr. Jeffrey English, Medical Director at Atlanta Neuroscience Institute (ANI), says, "There are added benefits to an event like this.
  • Up to one billion people are living with a neurological disorder — 100 million of which live in the United States.

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

Retrieved on: 
Thursday, February 16, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, The Lancet, CGRP, Pfizer, PFE, Albert Einstein College of Medicine, Phonophobia, MBS, NYSE, Department of Neurology, Xuanwu hospital, Patient, Freedom, Lancet Neurology, Neurology, Photophobia, Migraine, Inc., Nausea, Neurological disorder, Pharmaceutical industry

Additionally, zavegepant demonstrated relief from migraine pain in 15 minutes, with relief lasting up to 48 hours for many patients.

Key Points: 
  • Additionally, zavegepant demonstrated relief from migraine pain in 15 minutes, with relief lasting up to 48 hours for many patients.
  • Zavegepant was well tolerated, and there were no serious adverse events reported in treated participants.
  • “This was the first Phase 3 clinical trial of a non-oral CGRP receptor antagonist developed for the acute treatment of migraine in adults.
  • Treatment with zavegepant was also associated with higher rates of return to normal functional ability at 30 minutes post treatment and two hours.

FAU, DELRAY MEDICAL CENTER, INSIGHTEC TEAM UP ON GROUNDBREAKING ALZHEIMER'S STUDY

Retrieved on: 
Monday, February 20, 2023
Caregiver, Brain, Health, Glass, Dementia, Hospital, Protein, Fields, Treatment, DeSantis, FAU, Traffic barrier, University, Patient, Florida Department of Elder Affairs, Safety, Head, Disease, Neurology, Myenteric plexus, Incidence, Biochemistry, BBB, Essential tremor, Clinical trial, Drinking, Neurosurgery, Research, Charles E. Schmidt College of Science, Death, DSM-IV codes, Alzheimer's Association, Partnership, FDA, Chemistry, Parkinson's disease, Neurological disorder, Medical imaging, Residential care, Pharmaceutical industry, Alzheimer's disease, Insightec

BOCA RATON, Fla., Feb. 20, 2023 /PRNewswire/ -- Delray Medical Center is the first hospital in Florida to treat an Alzheimer's disease patient using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted in collaboration with Florida Atlantic University's Institute for Human Health and Disease Intervention (I-Health).

Key Points: 
  • The Delray Medical Center patient enrolled in the clinical trial received the first of three treatments at the hospital on Feb. 15.
  • "Delray Medical Center is proud and excited to be a leader in this effort to determine the safety and efficacy of this potentially revolutionary treatment for Alzheimer's patients," said Lloyd Zucker, M.D., FAANS, a board-certified neurosurgeon and medical director of neurosurgery at Delray Medical Center.
  • "The study will help determine whether the use of this non-invasive focused ultrasound technology can lead to cognitive improvement in patients with Alzheimer's disease."
  • "We are excited to collaborate with Delray Medical Center, Insightec and others on this groundbreaking technology that will create the next generation of patient care for Alzheimer's disease and other neurodegenerative disorders."

CHOP Researcher Leads International Panel in Developing First-Ever Clinical Diagnosis Guidelines for MOGAD

Retrieved on: 
Friday, February 17, 2023
Consensus, Online, The Lancet, Brain, Spinal cord, Paratriathlon, Confusion, Child, Mayo Clinic, Diagnosis, Clinical professor, Seizure, Division, Weakness, Patient, Hospital, Inflammation, Lancet Neurology, Cuban Neuroscience Center, MOG, DSM-IV codes, MOGAD, Immune system, CHOP, International, Antibody, Disease, Multiple sclerosis, Somnolence, Central nervous system, Neurological disorder, MS, Encephalopathy, Medical imaging, Neurology, MD

PHILADELPHIA, Feb. 17, 2023 /PRNewswire/ -- An international panel led by a pediatric neuroimmune expert and co-director of the Neuroscience Center at Children's Hospital of Philadelphia (CHOP) has established new criteria for properly diagnosing myelin oligodendrocyte glycoprotein antibody-associated diseased (MOGAD), a neurological disorder that causes inflammation and potential damage of the brain, spinal cord and optic nerves. While further validation is needed, these proposed guidelines, recently published in The Lancet Neurology, are the first clinical guidelines for MOGAD and provide an important framework for distinguishing MOGAD from other neurological disorders.

Key Points: 
  • While further validation is needed, these proposed guidelines, recently published in The Lancet Neurology , are the first clinical guidelines for MOGAD and provide an important framework for distinguishing MOGAD from other neurological disorders.
  • MOGAD is a demyelinating disorder of the central nervous system, meaning that damage is being caused to the myelin, or protective covering, of pathways in the brain.
  • To formulate these clinical guidelines for diagnosis, the international team conducted an extensive literature review and structured process and then derived international consensus criteria to aid in the diagnosis of MOGAD.
  • Banwell et al, "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force

Retrieved on: 
Friday, February 3, 2023
Machine learning, Neurological disorder, Drug discovery, Wind, Management

CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that on January 31, 2023 its Board of Directors determined it was appropriate to conduct a reduction in force as soon as practical so as to preserve cash to allow the Company, through its advisors including LifeSci Capital, to continue to pursue satisfactory strategic alternative transactions and/or execute an orderly wind down of the Company, if necessary.

Key Points: 
  • CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.
  • The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning.
  • On January 4, 2023, the Company announced it had engaged LifeSci Capital to assist the Board in evaluating potential strategic options.
  • To arrange a time to meet with the management team, please contact Hany Awadalla at LifeSci Capital at [email protected] .

CeCe Migraine Management App Syncs With CEFALY Connected Device to Provide Personalized Migraine Insights

Retrieved on: 
Wednesday, January 18, 2023
CeCe, Neurological disorder, Trigeminal nerve, FDA, PDF, Telephony, Migraine, Satellite navigation device, Medical device

DARIEN, Conn., Jan. 18, 2023 /PRNewswire/ -- The award-winning CeCe Migraine Management app now offers users an unprecedented level of insight into their migraine treatments with the CEFALY Connected device.

Key Points: 
  • DARIEN, Conn., Jan. 18, 2023 /PRNewswire/ -- The award-winning CeCe Migraine Management app now offers users an unprecedented level of insight into their migraine treatments with the CEFALY Connected device.
  • The latest version of the CeCe app pairs with the Bluetooth-enabled CEFALY Connected so users can track CEFALY treatments and log migraine attacks on their mobile device.
  • When a user pairs their CEFALY Connected device with the CeCe app, they can:
    Download a PDF report with their unique migraine patterns and treatment data to share with healthcare providers.
  • "When used in conjunction with the CEFALY Connected, however, the CeCe app gives users the ability to truly understand their migraine treatment journey.

When A Child's Concussion is Cause for Concern - Free Webinar

Retrieved on: 
Thursday, January 12, 2023
Rehabilitation, MPH, Pittsburgh, University, Parent, MS, Physical medicine and rehabilitation, Virginia Commonwealth University, University of Pittsburgh, Hack, USAMRMC, Head injury, Trauma, Emergency department, Department of Defense Education Activity, CISD, PPCS, TBI, Adolescence, Research, Government budget balance, Tactical Combat Casualty Care, Concussion, Traumatic brain injury, Brain damage, CTI Education Group, Neurological disorder, MD, Nature, Neurosurgery

GRAND RAPIDS, Mich., Jan. 12, 2023 /PRNewswire/ -- Contact sports, childhood falls, and car accidents can result in concussive injuries with a lasting impact.  Fusion Education Group will host a free webinar about traumatic brain injuries and the potential recovery paths available to children.

Key Points: 
  • GRAND RAPIDS, Mich., Jan. 12, 2023 /PRNewswire/ -- Contact sports, childhood falls, and car accidents can result in concussive injuries with a lasting impact.
  • Fusion Education Group will host a free webinar about traumatic brain injuries and the potential recovery paths available to children.
  • One in four children who suffered a minor head injury is likely to suffer from chronic post-concussion syndrome.
  • Families are encouraged to register for the webinar to discover if the trauma from a head injury is impacting their student's learning.

BrainTree Nutrition Onboarded Former NFL Players and Scientists to Create Its Product Line

Retrieved on: 
Wednesday, January 25, 2023
NFL, National Football League, Relaxation, Sleep, Neurology, Cardiology, Neurological disorder, Immune system, Braintree, Research, AFL, Athlete, Alzheimer's disease, Physician, Dietary supplement

Austin, Texas--(Newsfile Corp. - January 25, 2023) - BrainTree Nutrition launched its line of products led by former National Football League (NFL) players Scott Solomon and Andrew Sendejo with the help of scientists in the fields of neurology, cardiology, and more.

Key Points: 
  • Austin, Texas--(Newsfile Corp. - January 25, 2023) - BrainTree Nutrition launched its line of products led by former National Football League (NFL) players Scott Solomon and Andrew Sendejo with the help of scientists in the fields of neurology, cardiology, and more.
  • BrainTree Nutrition's products help solve the problem existing within the National Football League since it was founded more than a hundred years ago.
  • BrainTree Nutrition's product line includes clinically studied ingredients for improving cognitive function, sleep, relaxation, and the immune system .
  • The company has quickly become a leader in sports nutrition, especially in the NFL where the number of athletes relying on BrainTree Nutrition to improve their brain health is growing.

Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia

Retrieved on: 
Monday, January 9, 2023
Dizziness, Headache, CNS, Pharmacokinetics, Safety, Fatigue, PK, Lightheadedness, SAD, AUC, Cmax, Neurological disorder, Orexin, Central nervous system, Patient, Somnolence, MAD, AES, Schizophrenia, UU, Pharmaceutical industry, Cerev Del

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced positive results from its Phase 1 study of CVN766 in healthy subjects. The trial was a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and pharmacokinetics (PK) of escalating single and multiple doses of CVN766 in 64 healthy subjects. This data, along with earlier preclinical studies, supports developing CVN766 as a potential treatment for negative and cognitive symptoms of schizophrenia.

Key Points: 
  • This data, along with earlier preclinical studies, supports developing CVN766 as a potential treatment for negative and cognitive symptoms of schizophrenia.
  • CVN766 was well tolerated with an excellent safety profile across all dose groups: Data across all dose cohorts showed that CVN766 was well tolerated with a favorable safety profile.
  • There were no serious adverse or dose-limiting adverse events (AEs), treatment-related discontinuations, or meaningful changes in clinical laboratory parameters or physical exams.
  • “We are encouraged with the safety and pharmacokinetics profiles observed in the Phase 1 trial for CVN766,” said Craig Thompson, chief executive officer of Cerevance.

ROSALIND FRANKLIN UNIVERSITY RESEARCHER AWARDED $1.3 MILLION TO INVESTIGATE MULTIDRUG RESISTANCE IN BRAIN DISEASES

Retrieved on: 
Wednesday, January 11, 2023
RFU, Cancer, MDR, Neurological disorder, Bipolar disorder, Cell membrane, Research, Death, Tourette syndrome, Alcoholism, Autism, Patient, Infection, Antiporter, Health, Huntington's disease, National Institute of General Medical Sciences, Schizophrenia, NIH, Rosalind Franklin University of Medicine and Science, Proteomics, Doctor of Philosophy, Parkinson's disease, Pharmaceutical industry, Medical device

NORTH CHICAGO, Ill., Jan. 11, 2023 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science structural biologist Min Lu , PhD, was recently awarded a four-year, $1.3 million grant from the National Institutes of General Medical Sciences to investigate new therapeutic strategies to combat multidrug resistance (MDR).

Key Points: 
  • NORTH CHICAGO, Ill., Jan. 11, 2023 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science structural biologist Min Lu , PhD, was recently awarded a four-year, $1.3 million grant from the National Institutes of General Medical Sciences to investigate new therapeutic strategies to combat multidrug resistance (MDR).
  • MDR poses a major challenge to the development of new drug therapies for cancer and infectious diseases.
  • "The problem of multidrug resistance in brain diseases limits the use of new drugs very early into their life cycle," he said.
  • "If we can overcome this resistance, we extend the therapeutic repertoire of these drugs for effective use in patients."